This study is currently not recruiting participants.

Phase II study of Rolapitant plus Olanzapine Palonosetron and Dexamethasone in Patients with Germ Cell Tumors undergoing 5-day Cisplatin-based Chemotherapy

Study on Investigational Medication for Nausea in Germ Cell Cancer Patients

Not Recruiting
18 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to test whether the drug rolapitant, an NK-1 Receptor Antagonist (NK1RA), (a drug used for the prevention of nausea [upset stomach] and vomiting caused by chemotherapy) can reduce symptoms of nausea and vomiting in patients with germ cell cancer that are receiving standard treatment with 5-day Cisplatin-based chemotherapy.

Detailed description of study

This is a prospective, single-arm phase II study in subjects with Metastatic germ cell cancer. This study will test whether the drug rolapitant, a NK-1 Receptor Antagonist (NK1RA), (a drug used for the prevention of nausea [upset stomach] and vomiting caused by chemotherapy) can reduce symptoms of nausea and vomiting in patients with germ cell cancer that are receiving standard treatment with 5-day Cisplatin-based chemotherapy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Germ Cell Tumor
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the effects of an investigational medication on reducing nausea and vomiting in patients with germ cell cancer undergoing chemotherapy. Germ cell cancer is a type of cancer that begins in the cells that give rise to sperm or eggs. The investigational medication is being tested for its ability to prevent nausea and vomiting, which are common side effects of chemotherapy.

Participants will receive the investigational medication alongside their standard 5-day Cisplatin-based chemotherapy. The study aims to see if the investigational medication can effectively reduce these side effects, improving the comfort and quality of life for patients.

  • Who can participate: Individuals aged 18 and older with metastatic germ cell cancer receiving standard 5-day Cisplatin-based chemotherapy may be eligible to participate.
  • Study details: Participants will receive rolapitant along with their usual chemotherapy treatment. The investigational medication is designed to reduce nausea and vomiting, which are common side effects of chemotherapy. No placebo is used in this study.
Updated on 19 Feb 2024. Study ID: 1711203191

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team